Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06453213 · ClinicalTrials.gov registry record · Phase 4
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
A Phase 4 study of Focal Onset Seizure, sponsored by SK Life Science.
- Active
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
- 19
- Study locations
NCT06453213 is a Phase 4 study of Focal Onset Seizure that is active but no longer recruiting, run by SK Life Science. The registered enrollment target is 49 participants. The trial reports 19 study locations across 13 states.
The verdict
NCT06453213, a Phase 4 study of Focal Onset Seizure, is active but no longer recruiting, sponsored by SK Life Science.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
- 19
- Study locations
Study Summary
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagnosed or recurrent POS/focal onset epilepsy.
Conditions Studied
Interventions
- DRUG Cenobamate
Study Locations (19)
Arizona
- Arizona Neuroscience Research - Phoenix
- Center For Neurosciences - Tucson
California
- Neuro Pain Medical Center - Fresno
- Hoag Physician Partners - Newport Beach
Connecticut
- Hartford Hospital - Hartford
- Yale School of Medicine - Yale-New Haven Hospital - New Haven
Florida
- Elite Clinical Research - Miami
- Knight Neurology - Rockledge
Michigan
- Henry Ford Health System - Detroit
- Wayne Neurology PLC - Plymouth
New York
- NY Neurology Associates - New York
- Mount Sinai Hospital - New York
Arkansas
- Clinical Trials Inc - Little Rock
Idaho
- Consultants In Epilepsy and Neurology - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2027-07-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06453213
The ClinicalTrials.gov registry entry for NCT06453213 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SK Life Science, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Focal Onset Seizure appearing as the primary indexed condition, and to 1 intervention - of which Cenobamate is the first listed.
NCT06453213 reports 19 study locations spanning 13 distinct geographic areas - top geographies include Arizona, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06453213 about?
NCT06453213 is a clinical study titled "Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy". Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinica...
What is the current status of trial NCT06453213?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2024-10-14. Estimated completion is 2027-07-09.
What conditions does trial NCT06453213 study?
This clinical trial studies the following conditions: Focal Onset Seizure.
What interventions are being tested in trial NCT06453213?
The interventions under investigation include: Cenobamate (DRUG).
Who is sponsoring clinical trial NCT06453213?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06453213 being conducted?
This trial has 19 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Onset Seizure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.